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Abstract
Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents
represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lym-
phoma, such as aberrant signal transduction pathways, which have led to the discovery and development of tar-
geted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are
examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small
molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the
targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This
review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of
mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.
Introduction
Despite remarkable advances in diagnosis and treatment,
lymphoma continues to rank as a leading cause of can-
cer-related mortality. Recent cancer statistics for the
United States project non-Hodgkin lymphoma (NHL) to
be the sixth most commonly diagnosed cancer in 2010
in both men and women, and the eighth and sixth lead-
ing cause of cancer-related death in men and women,
respectively [1]. Based on data from national cancer
registries, 65,540 new cases of NHL and 20,210 deaths
from NHL are estimated to occur in 2010. In contrast,
Hodgkin lymphoma (HL) is less common (8,490 esti-
mated new cases in 2010) and is associated with fewer
deaths (1,320 estimated deaths in 2010) [1]. In the Eur-
opean Union, reported NHL estimates for the year 2006
were even higher, with 72,800 new cases and 33,000
deaths [2].
Current treatments for NHL are not optimally effec-
tive, with relapse and resistance to chemotherapy com-
mon and the risk of secondary malignancies an ongoing
concern. Long-term prognosis in patients who relapse
with aggressive NHL, such as diffuse large B-cell lym-
phoma (DLBCL) and mantle cell lymphoma (MCL),
after induction therapy typically is dismal [3,4]. Discov-
ery of new treatments that prolong survival and are less
toxic represents an urgent unmet medical need.
Intensive research efforts that were focused on better
understanding the molecular pathogenesis of lymphoma
have paved the way toward identifying and testing tar-
geted therapeutics [5].
Delineation of signal transduction mechanisms
involved in the pathogenesis of lymphoma has revealed
new therapeutic targets for clinical investigation
(Table 1) [6-14]. For example, the ubiquitin-proteasome
signaling pathway, which is a fundamental component
of cellular proliferation and survival, mediates the degra-
dation of proteins involved in the regulation of cell
growth [15]. The proteasome activates nuclear factor-B
(NF-B) signaling by degrading IB kinase (eg, the NF-
B inhibitory protein), resulting in the promotion of
tumor growth and metastasis [15]. Elucidation of this
regulatory signaling pathway identified IBk i n a s ea sa
molecular target for development of drugs with activity
against lymphoma. Bortezomib (Velcade®) is the proto-
type small-molecule protease inhibitor that is approved
for the treatment of relapsed/refractory MCL and multi-
ple myeloma [15,16].
The phosphoinositide 3-kinase (PI3K)/Akt signaling
pathway (Figure 1) is another important signal transduc-
tion pathway that is aberrantly activated in various differ-
ent types of cancer, including many hematologic
malignancies [8]. PI3K is a lipid kinase that is activated by
a variety of cellular input signals, such as growth factor
receptor tyrosine kinase stimulation. Activated PI3K
enables recruitment of the serine/threonine kinase Akt to
the cell membrane where it undergoes phosphorylation.
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intracellular signaling proteins [8]. One downstream target
of Akt is the mammalian target of rapamycin (mTOR), a
cytoplasmic serine/threonine kinase that, when activated,
promotes mRNA translation and protein synthesis, result-
ing in the regulation of cell growth and proliferation, cellu-
lar metabolism, and angiogenesis [8]. The mTOR pathway
is aberrantly activated in many hematologic malignancies,
including some forms of NHL and HL [8-10]. The mTOR
inhibitors everolimus (Afinitor®) and temsirolimus (Tori-
sel®) are currently under clinical investigation for the treat-
ment of NHL and HL, and ridaforolimus (formerly
deforolimus) is being evaluated in patients with hematolo-
gical malignancies including lymphoma.
Other investigational targeted therapies are of interest in
the treatment of NHL and HL (Table 1). Lenalidomide
(Revlimid®) is a derivative of thalidomide that is approved
for use in combination with dexamethasone for the treat-
ment of previously treated multiple myeloma [17]. Lenali-
domide is currently being investigated in a variety of solid
tumors and other hematologic malignancies, including
lymphoma [17]. While the exact mechanism is not known,
lenalidomide is believed to exert anti-metastatic, anti-pro-
liferative, and immunomodulatory activities [11,17].
Sunitinib (Sutent®) and sorafenib (Nexavar®) are tyrosine
kinase inhibitors that interrupt tumor proliferation and
angiogenesis by inhibiting vascular endothelial growth
factor (VEGF) and platelet-derived growth factor (PDGF)
receptors [12,13]. The histone deacetylase inhibitors
(Table 1) represent an emerging therapeutic approach
that targets aberrant gene expression, putatively blocking
the development of malignant phenotypes (eg, epigenetic
therapy) [14,18]. Histones are structural proteins involved
in the expression of genes that regulate tumor cell differ-
entiation and apoptosis [14,18]. Vorinostat (Zolinza®),
romidepsin (FK228), valproic acid, and panobinostat
(LBH589) are some of the histone deacetylase inhibitors
(HDACIs) currently being investigated for clinical activity
[14,18,19].
Herein we review the experience with targeted treat-
ments for lymphoma that have advanced from phase I
to phase III clinical trials. We will focus our discussion
primarily on published data in NHL, including MCL
and DLBCL. It is hoped that the wealth of information
being discovered in the molecular pathogenesis of lym-
phoma and the development of targeted therapeutics for
these aberrant pathways will identify highly specific, less
toxic agents for the treatment of lymphomas.
Table 1 Investigational therapeutic targets in lymphoma treatment
Pathway/Protein Oncogenic Mechanism Molecular Target(s) Drug Class Investigational
Drugs in Clinical
Trials
Ubiquitin-
proteasome
pathway [6,7]
Dysregulation of intracellular cell cycle proteins NF-B inhibitory
protein (IB)
Small-molecule
proteasome
inhibitors
Bortezomib (PS-341,
Velcade™)
Akt/mTOR
pathway [8-10]
Aberrant activation of mTOR-mediated regulation of cell
growth, proliferation, apoptosis, angiogenesis, nutrient
uptake
mTORC1 (mTORC2?) mTOR inhibitors Temsirolimus (CCI-
779, Torisel®)
Everolimus (RAD001,
Afinitor®)
Ridaforolimus
(formerly deforolimus,
AP23573)
Cell-mediated
immunity,
cytokines [11]
Aberrant activation of prosurvival cytokines and cellular
immune response
TNF-a, IL-6, IL-8, and
VEGF; T cells and NK
cells
Immunomodulatory
drugs (IMiDs)
Lenalidomide
(Revlimid®)
VEGF receptors,
PDGF receptors
[12,13]
Tumor proliferation, angiogenesis Tyrosine kinase Tyrosine kinase
inhibitors
Sunitinib (SU11248,
Sutent®)
Sorafenib (Nexavar®)
Histone
deacetylase [14]
Dysregulated histone deacetylation in promoters of
growth regulatory genes (gene silencing)
Histone deacetylase Histone deacetylase
inhibitors (HDACIs)
Vorinostat (Zolinza®)
Romidepsin (FK228)
Valproic acid
Panobinostat
(LBH589)
Others
Abbreviations: IL-6 = interleukin-6; IL-8 = interleukin-8; mTOR = mammalian target of rapamycin; PDGF = platelet-derived growth factor; PI3K = phosphoinositide
3-kinase; TNF-a = tumor necrosis factor-alpha; VEGF = vascular endothelial growth factor.
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The clinical trial experience to date for bortezomib
treatment of lymphoma includes studies of mixed lym-
phoma populations and studies that limited enrollment
to patients with MCL, DLBCL, or HL (Table 2)
[20-33].
Relapsed/refractory mantle cell lymphoma
Three phase II studies evaluated the safety and anti-
tumor response of bortezomib in a total of 125
evaluable patients with various relapsed/refractory lym-
phomas (Table 2). Patients were heavily pretreated and
had relapsed disease or tumors that were refractory to
Input
mRNA translation
Protein synthesis
PI3K Akt
TSC1/2
Rheb
mTOR
p70S6K
4E-BP1
rpS6 eIF-4B
Figure 1 The PI3K/Akt signaling pathway. Reprinted with permission from Altman JK, Platanias LC: Exploiting the mammalian target of
rapamycin pathway in hematologic malignancies. Curr Opin Hematol. 2008, 15:88-94.
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Reference Study Evaluable Patients ORR (CR + PR)
Treatment-naïve MCL
Kahl et al 2008
[20]
Phase II, single-arm, VcR-CVAD followed by
maintenance rituximab therapy
N = 30 90%
Relapsed/refractory MCL (and other lymphomas)
O’Connor et al
2005 [21]
Phase II, single-arm, monotherapy (1.5 mg/m
2 days
1, 4, 8, 11 every 21 days)
N = 24: MCL (n = 10), follicular lymphoma (n = 9), small
lymphocytic lymphoma or CLL (n = 3), marginal zone
lymphoma (n = 2)
MCL 50%
Follicular
lymphoma 78%
Small
lymphocytic
lymphoma or
CLL 0%
Marginal zone
lymphoma 100%
Gerecitano et al
2009 [22]
Extension of O’Connor et al 2005 trial: continuing
patients switched to weekly bortezomib 1.8 mg/m
2
N = 22: MCL (n = 8), follicular lymphoma (n = 14) MCL 25%
Follicular
lymphoma 14%
Goy et al 2005
[23]
Phase II, single-arm, monotherapy (1.5 mg/m
2 days
1, 4, 8, 11 every 21 days)
N = 50: MCL (n = 29), other B-cell lymphomas (n = 21) MCL 41%
Other B-cell
lymphomas 19%
Strauss et al 2006
[24]
Phase II, single-arm, monotherapy (1.3 mg/m
2 days
1, 4, 8, 11 every 21 days)
N = 48: MCL (n = 24), follicular lymphoma (n = 11),
other lymphomas (n = 13)
MCL 29%
Follicular
lymphoma 18%
Others 23%
Relapsed/refractory MCL
PINNACLE, Fisher
et al 2006 [25]
Phase II, single-arm, monotherapy (1.3 mg/m
2 days
1, 4, 8, 11 every 21 days)
N = 141 33%
Updated
PINNACLE,
a Goy
et al 2009 [26]
Phase II, single-arm, monotherapy (1.3 mg/m
2 days
1, 4, 8, 11 every 21 days)
N = 55 29%
Belch et al 2007
[27]
Phase II, single-arm, monotherapy (1.3 mg/m
2 days
1, 4, 8, 11 every 21 days)
N = 28 46%
O’Connor et al
2009 [28]
Phase II, single-arm monotherapy (1.5 mg/m
2 days
1, 4, 8, 11 every 21 days)
N=3 6
b 47%
Weigert et al
2009 [29]
Multicenter observational study of R-HAD+B salvage
regimen:
- bortezomib (1.5 mg/m
2 days 1, 4)
- cytarabine (2,000 mg/m
2 days 2, 3
c)
- dexamethasone (40 mg days 1-4)
- Rituximab (375 mg/m
2 on day 0 for patients not
refractory to prior rituximab-containing regimens)
N = 8 50%
DLBCL
Dunleavy et al
2009 [30]
Phase I/II, 2-part study of bortezomib monotherapy
(part A) followed by bortezomib plus DA-EPOCH
(part B)
N = 47 (n = 23 part A, n = 44 part B) Part A 4%
Part B 34%
Relapsed/refractory Hodgkin lymphoma
Trelle et al 2007
[31]
Phase II, bortezomib (1.3 mg/m
2) plus
dexamethasone (20 mg) on days 1, 4, 8, 11 every
21 days
N = 12 0% (17% SD, 83%
PD)
Blum et al 2007
[32]
Phase II, single-arm, monotherapy (1.3 mg/m
2 on
days 1, 4, 8, 11 every 21 days)
N = 29 0% (30% SD, 70%
PD)
Mendler et al
2008 [33]
Phase II, single-arm bortezomib (1 mg/m
2 on days
1, 4, 8, 11) and gemcitabine (800 mg/m
2 on days 1,
8) every 21 days
N = 18 22%
Abbreviations: MCL - mantle-cell lymphoma, ORR - overall response rate, CR - complete response, PR - partial response, CLL - chronic lymphocytic leukemia,
DLBCL - diffuse large B-cell lymphoma, DA-EPOCH - doxorubicin-based chemotherapy (etoposide, vincristine, doxorubicin, with cyclophosphamide and
prednisone), R-HAD+B - bortezomib, high-dose cytarabine, dexamethasone, SD - stable disease, PD - progressive disease; VcR-CVAD - bortezomib, rituximab,
cyclophosphamide, doxorubicin, vincristine and dexamethasone.
aOriginal PINNACLE publication reported data from median follow-up period of 13.4 months [25]; updated publication described data from median follow-up of
26.4 months [26]
bThe 36 evaluable patients included 11 patients whose outcome was reported by O’Connor et al 2005 [21,28]
cPatients ≥60 years of age were treated with 1,000 mg/m
2 [29]
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evaluable patients in these 3 studies had MCL. Bortezo-
mib was administered as monotherapy using a 21-day
dosing cycle of 1.5 mg/m
2 or 1.3 mg/m
2 twice weekly
for 2 weeks followed by a 1-week rest [21,23,24]. Overall
response rates for the 1.5 mg/m
2 dose were 50% (1
unconfirmed complete response [uCR]/4 partial
responses [PR]) [21] and 41% (6 CR/6 PR) [23]. Of the
24 evaluable patients who were treated with bortezomib
1.3 mg/m
2, 29% achieved a measurable clinical response
(1 CR/6 PR) [24]. Of 33 patients with MCL in one
study, the median time to disease progression was 3.5
months, with an estimated progression-free survival at 6
months of 42% [23].
Three other studies examined the efficacy and safety
of bortezomib in cohorts that consisted only of patients
with MCL (Table 2). In the PINNACLE trial, bortezo-
mib 1.3 mg/m
2 was administered to 141 evaluable
patients according to the same 21-day cycle as in earlier
studies, and 33% of patients responded to treatment (2
uCR/9 CR/36 PR) [25]. Although the median overall
survival was not reached by the data cut-off point, 66%
of patients remained alive after a median follow-up per-
iod of 13.4 months, and the 1-year survival probability
was 94.3% for responding patients and 69.3% for all
patients [25]. When the median follow-up was extended
to 26.4 months, the median progression-free survival
and median time to next treatment were, respectively,
20.3 and 23.9 months (complete responders), 9.7 and
13.3 months (partial responders), and 12.4 and 14.3
months (all responders) [26]. Findings from 2 smaller
studies of bortezomib monotherapy in patients with
MCL demonstrated overall response rates of 46% [27]
and 47% [28].
Based on in vitro data showing synergy between borte-
zomib and conventional chemotherapy [34], Weigert
and associates administered R-HAD+B, which is a novel
regimen of bortezomib (1.5 mg/m
2 twice weekly every
21 days), high-dose cytarabine, and dexamethasone to 8
patients with advanced MCL (Table 2) [29]. Patients not
refractory to prior rituximab regimens also received
rituximab on day 0 [29]. Four patients were withdrawn
from the study due to lack of response, but the 4 other
patients completed 4 treatment cycles and achieved a
CR (n = 2) or PR (n = 2) [29].
In addition to the studies combining bortezomib in
the relapsed/refractory setting for NHL, 2 recent studies
have assessed bortezomib in combination with other
agents in previously untreated patients with NHL
[20,35]. Bortezomib has been combined with rituximab,
cyclophosphamide, doxorubicin, vincristine, and dexa-
methasone (VcR-CVAD) in the treatment of patients
with untreated MCL in a phase II trial [20]. All patients
achieving at least a PR after completing 6 cycles of the
VcR-CVAD were offered maintenance rituximab therapy
for 5 years. All 30 enrolled patients had completed the
induction phase of the VcR-CVAD chemotherapy at the
time of reporting. A 90% overall response rate was
reported after VcR-CVAD with 77% CR/uCR and 13%
PR with 10% of patients experiencing progressive disease
during the induction chemotherapy. With a median fol-
low-up of almost 18 months, the 18-month progression-
free and overall survival was reported at 73% and 97%,
respectively. Another trial incorporated bortezomib in
combination with R-CHOP chemotherapy (rituximab,
cyclophosphamide, hydroxydaunorubicin, vincristine,
prednisone) in a phase I trial in patients with previously
untreated aggressive NHL [35]. In this study, standard
R-CHOP was given on a 21-day cycle and bortezomib
was administered on days 1 and 4 of each cycle at 0.7
mg/m
2 (4 patients), 1.0 mg/m
2 (9 patients), or 1.3 mg/
m
2 (7 patients). The histologic subtypes included both
MCL and diffuse large B-cell lymphoma (DLBCL). The
maximum tolerated dose was not reached and the 1.3
mg/m
2 dose was well tolerated. Neuropathy was a com-
mon side effect reported in 65% of patients [35].
Combination therapy with bortezomib is being evalu-
ated further in an ongoing open-label, international
phase III study. In this study, standard R-CHOP is being
compared with a regimen of rituximab, cyclophospha-
mide, doxorubicin, bortezomib, and prednisone (VcR-
CAP) in patients with newly diagnosed MCL who are
not eligible for bone marrow transplantation
(NCT00722137).
Other lymphomas
Bortezomib monotherapy does not appear to have clini-
cally meaningful anti-tumor activity in DLBCL, but
when combined with chemotherapy, 34% of patients in
one study responded to treatment (Table 2) [30]. Borte-
zomib also has been evaluated in patients with relapsed/
refractory HL (Table 2), but none achieved a clinical
response with bortezomib monotherapy [32] or with
bortezomib plus dexamethasone [31]. A minimal clinical
response (1 CR/3 PR) was observed with the combina-
tion of bortezomib and gemcitabine in 18 patients with
DLBCL, but the investigators concluded that this combi-
nation should not be pursued due to grade 3/4 hepato-
toxicity [33].
Toxicity
Neutropenia and thrombocytopenia are common hema-
tologic toxicities reported during twice-weekly bortezo-
mib treatment [21,23,24,26,27,30]. Fatigue, peripheral
neuropathy, and gastrointestinal disturbances were the
most frequently reported non-hematologic adverse
Johnston et al. Journal of Hematology & Oncology 2010, 3:45
http://www.jhoonline.org/content/3/1/45
Page 5 of 10events associated with bortezomib [23,25-27]. The most
common dose-limiting toxicities during treatment of
MCL with twice-weekly bortezomib monotherapy (1.3
mg/m
2 or 1.5 mg/m
2) were peripheral neuropathy, fati-
gue, and thrombocytopenia [21,23-25]. All of the 8
patients with advanced MCL who were treated with bor-
tezomib plus high-dose cytarabine and dexamethasone
developed grade 3/4 hematologic toxicity, 2 developed
grade 3 febrile neutropenia, and 7 required G-CSF res-
cue [29]. In a continuation of one phase II monotherapy
trial [21], Gerecitano and colleagues administered borte-
zomib monotherapy once-weekly (1.8 mg/m
2)a n d
concluded that weekly dosing is less toxic than the
twice-weekly schedule but resulted in a lower clinical
response rate (2 PR of 8 assessable patients with MCL)
(Table 2) [22].
mTOR Inhibitors
The rapamycin analogs everolimus and temsirolimus are
mTOR inhibitors that have been approved for treatment
of resistant renal cell carcinoma. Everolimus is adminis-
tered orally, and temsirolimus intravenously. Based on
in vitro activity of mTOR inhibitors in numerous lym-
phoma cell lines [36,37], both everolimus and temsiroli-
mus have completed phase II clinical trials in NHL.
Ridaforolimus and sirolimus are other mTOR inhibitors
that also are in clinical testing for the treatment of lym-
phomas (Table 3) [38-46].
Relapsed/refractory mantle cell lymphoma
The mTOR inhibitors, everolimus, temsirolimus, and
ridaforolimus, have been evaluated in phase I and II
trials of patients with relapsed/refractory MCL (Table 3).
Table 3 Clinical trial experience with mTOR inhibitors in lymphoma
Reference Study Evaluable Patients ORR (CR + PR)
Relapsed/refractory MCL (and other lymphomas)
Everolimus
[38]
Phase II, single-arm, monotherapy (10 mg/day PO) MCL (n = 19)
DLBCL (n = 47)
Follicular grade 3 (n = 8)
Other lymphomas (n = 3)
MCL 32%
DLBCL 30%
Follicular grade
III 38%
Other
lymphomas 0%
Everolimus
[39]
Phase I/II single-arm, monotherapy (5 or 10 mg/day PO) MCL (n = 4)
Other hematologic
malignancies (n = 23)
MCL 0%
Other 4%
Temsirolimus
[40]
Phase II, single-arm, monotherapy (250 mg IV weekly) MCL (N = 34) 38%
Temsirolimus
[41]
Phase II, single-arm, monotherapy (25 mg IV weekly) MCL (N = 27) 41%
Temsirolimus
[42]
Phase III, monotherapy (175 mg IV weekly for 3 weeks, then 25 mg [n = 54] or 75 mg
IV weekly [n = 54]) vs investigator-chosen chemotherapy (n = 54)
MCL (N = 162) Temsirolimus
25 mg 6%
Temsirolimus
75 mg 22%
Investigator-
chosen 2%
Ridaforolimus
[43]
Phase II, single-arm, monotherapy (12.5 mg/day IV on days 1-5 every 2 weeks) MCL (n = 9)
Other hematologic
malignancies (n = 43)
MCL 33%
Others 5%
Waldenström macroglobulinemia
Everolimus
[44]
Phase II, single-arm, monotherapy (10 mg/day) WM (N = 50) 42% (PR)
Hodgkin lymphoma
Everolimus
[45]
Phase II, single-arm, monotherapy (10 mg/day) HL (N = 19) HL 47%
GVHD
Sirolimus [46] Retrospective chart review, sirolimus conditioning (12 mg loading dose days 1-3, then
4 mg daily) vs standard conditioning
GVHD prophylaxis after
HSCT for lymphoma (N =
126)
a
Overall survival:
Sirolimus 66%
Standard
conditioning
38%
Abbreviations: CR - complete response, DLBCL - diffuse large B-cell lymphoma, GVHD - graft-versus-host disease, HL - Hodgkin’s lymphoma, HSCT - hematopoietic
stem cell transplant, IV - intravenously, MCL - mantle-cell lymphoma, ORR - overall response rate, PO - orally, PR - partial response, WM - Waldenström
macroglobulinemia.
aOverall survival reported as 3-year survival for patients receiving reduced intensity conditioning [46]
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(10 mg/day for 4-week cycles) was evaluated in a
phase II trial of 77 patients with relapsed aggressive
NHL, including 19 patients with MCL and 47 patients
with DLBCL [38]. The overall response rates were
30% (3 uCR/20 PR) for all patients, 32% for MCL, and
30% for DLBCL [38]. The median duration of
response in patients achieving a CR or PR was 5.7
months, and of these patients, 5 remained progres-
sion-free at 12 months [38]. Monotherapy with evero-
limus was first evaluated in a phase I/II trial of 26
heavily pre-treated patients with relapsed or refractory
MCL (n = 4) or other hematologic malignancies
(n = 23) [39]. Everolimus modulated mTOR signaling
i n6o f9p a t i e n ts a m p l e sw i t h i n2 4h o u r sa sd e m o n -
strated by simultaneous inhibition of the downstream
effectors, p70S6K and 4E-BP1 [39]. None of the
4 patients with MCL in this cohort achieved a clinical
response to everolimus [39].
Temsirolimus has been studied in 2 phase I/II trials
and 1 large phase III trial of patients with MCL (Table 3).
The response rate to a 250-mg/week course of temsiroli-
mus monotherapy in patients with advanced MCL was
38% (N = 34; 1 CR/12 PR) [40], which was similar to the
4 1 %r e s p o n s er a t e( N=2 7 ;1C R / 1 0P R )a c h i e v e db ya
similar cohort after treatment with a 10-fold lower dose
of temsirolimus (25 mg/week) [41]. However, the 25-mg
dose was associated with lower rates of hematologic toxi-
city, specifically thrombocytopenia [41]. Based on these
findings, a large phase III trial of temsirolimus monother-
apy was conducted. Patients with heavily pre-treated
relapsed/refractory MCL (N = 162) were randomized to
open-label treatment with investigator-chosen, pre-
approved chemotherapy regimens or 1 of 2 regimens of
temsirolimus monotherapy (175 mg/week for 3 weeks
followed by either 25-mg or 75-mg weekly) [42]. The
overall response rate was 6% for the 25-mg dose and 22%
for the 75-mg dose, the latter being significantly higher
(p = 0.0019) compared with investigator-chosen treat-
ment (2%) [42]. Median progression-free survival was 3.4
months (25 mg), 4.8 months (75 mg), and 1.9 months
(investigator-chosen; p = 0.0009 vs 75 mg) [42].
The anti-tumor activity of ridaforolimus, another
intravenously administered mTOR inhibitor, has been
evaluated in a phase II study of 52 patients with hema-
tologic malignancies (including 9 patients with MCL)
(Table 3) [43]. Patients were treated with ridaforolimus
monotherapy 12.5 mg daily for days 1 to 5 every 2
w e e k s[ 4 3 ] .O ft h e9p a t i e n t sw i t hM C L ,3a c h i e v e da
partial response for an overall response rate of 33% [43].
Waldenström macroglobulinemia
A phase II trial of everolimus monotherapy (10 mg/day)
was conducted in 50 patients with relapsed or relapsed/
refractory Waldenström macroglobulinemia (WM)
(Table 3) [44]. After a median treatment duration of
2m o n t h s( r a n g e :1t o1 0m o n t h s ) ,2 1p a t i e n t s( 4 2 % )
achieved a partial response. No patient had a CR. The
median duration of response had not been reached by
the time of publication, but 16 of the 21 patients contin-
ued to respond after a median 6.6-month follow-up
(range: 1 to > 18.2 months) [44].
Hodgkin lymphoma
The anti-tumor activity of everolimus monotherapy (10
mg/day) also was examined in a phase II study of 19
heavily pre-treated patients with relapsed HL (Table 3)
[45]. The overall response rate was 47% (1 CR/8 PR),
with a median duration of response of 7.1 months [45].
A multicenter trial has begun enrollment in the
United States to confirm the activity of everolimus
monotherapy in patients with relapsed/refractory HL
(NCT01022996).
Graft-versus-host disease
Armand and colleagues conducted a retrospective chart
review of patients who underwent allogenic hematopoie-
tic stem-cell transplantation for lymphoma [46]. Patients
chosen for inclusion received graft-versus-host disease
(GVHD) prophylaxis with the mTOR inhibitor sirolimus
(12-mg loading doses on days 1-3 followed by 4 mg
daily) or standard GVHD prophylaxis (cyclosporine or
tacrolimus alone or in combination with methotrexate).
Of 126 patients who received reduced intensity condi-
tioning with sirolimus (n = 103) or with standard regi-
mens (n = 23), the 3-year overall survival rate was 66%
(p = 0.007 vs no sirolimus) in the sirolimus arm and
38% in the no-sirolimus group with a corresponding 3-
year progression-free survival of 44% (p = 0.001 vs no
sirolimus) and 17%, respectively [46].
Diffuse large B-cell lymphoma
As previously noted, everolimus monotherapy has been
evaluated in a phase II trial in patients with relapsed/
refractory aggressive NHL, including 47 patients with
DLBCL who achieved an overall response rate of 30%
[38]. Several ongoing investigator-initiated trials are
evaluating combining everolimus with other agents in
the treatment of NHL. In addition, the PIvotaL Lym-
phoma triAls of RAD001 (PILLAR-2; NCT00790036), an
ongoing phase III maintenance trial of everolimus in
poor-risk patients with DLBCL who achieved a CR with
R-CHOP chemotherapy, has begun enrolling patients
(NCT00790036).
Toxicity
Thrombocytopenia, neutropenia, and anemia are the
most commonly reported hematologic toxicities reported
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mus, temsirolimus, and ridaforolimus [38-44]. Not sur-
prisingly, thrombocytopenia reported during temsirolimus
250 mg/week (100%) was more common than during
treatment with the lower dose of 25 mg/week (39%)
[40,41]. Differences in the rates of thrombocytopenia
were less marked for temsirolimus 75-mg weekly (59%)
versus 25-mg weekly (52%) [42]. Fatigue, mucositis,
hyperglycemia, diarrhea, anorexia/weight loss, and hyper-
lipidemia are commonly occurring non-hematologic toxi-
cities seen during mTOR inhibitor treatment [38-44].
Thrombocytopenia was a commonly reported reason for
treatment delay or dose reduction [38,40,41,45].
Pulmonary toxicity can be observed with mTOR inhi-
bitor therapy. Pulmonary symptoms, such as increased
cough, dyspnea, and pleural effusion, have been reported
during treatment with both everolimus and temsiroli-
mus [38,42,44,45]. It is difficult to compare rates of pul-
monary toxicity for the different mTOR inhibitors given
non-standard descriptions of adverse events and the
lack of direct, head-to-head studies. Nevertheless, rates
of grade 3/4 dyspnea and other pulmonary symptoms
were similar for everolimus (21%) and temsirolimus
(16%) in 2 monotherapy studies [42,45]. Pulmonary
symptoms associated with mTOR inhibition usually can
be managed by interrupting treatment and restarting at
a lower dose [38,44,45].
Thalidomide Derivatives
The thalidomide derivative, lenalidomide, has been eval-
uated in a phase II multicenter study in patients with
relapsed/refractory aggressive NHL [47]. Open-label
treatment consisted of lenalidomide 25 mg daily for the
first 21 days of every 28-day cycle; patients continued
treatment for 52 weeks unless toxicity or disease pro-
gression occurred [47]. Of the 49 evaluable patients, 26
had DLBCL, 15 had MCL, 5 had grade 3 follicular lym-
phoma, and 3 had transformed low-grade lymphoma
[47]. Overall response rates were 35% (4 uCR/2 CR/11
PR) for all 49 patients, 19% for DLBCL (2 uCR/1 CR/2
PR), and 53% for MCL (1 uCR/1 CR/6 PR) [47]. For the
entire population of 49 patients, the median duration of
response was estimated to be 6.2 months, and the med-
ian progression-free survival was 4.0 months [47]. The
most common grade 3/4 hematologic toxicities were
neutropenia, thrombocytopenia, and leukopenia [47].
Neutropenia, thrombocytopenia, and fatigue were
the toxicities most likely to necessitate a reduction in
dose [47].
Trial investigators updated the clinical outcome of the
15 patients with MCL [48]. The overall response rate
remained at 53% (3 CR/5 PR), with 1 patient converting
from a partial response to a complete response [48]. The
median duration of response for the patients with MCL
in the updated report was 13.7 months with a median
progression-free survival of 5.6 months [48]. Hematologic
and dose-limiting toxicities were consistent with that
described in the initial report [47,48]. Based on these
promising findings, a phase III multinational, placebo-
controlled, first-line maintenance study of lenalidomide
in patients with MCL is planned (NCT01021423).
Discussion
Effective therapies for patients with lymphoma are
urgently needed. Targeted therapy based on signal trans-
duction pathway alterations detected in lymphomas
offers the hope of reaching this goal. Monotherapy with
the proteasome inhibitor, bortezomib, has shown
efficacy in MCL, and combination therapy with conven-
tional chemotherapy regimens also appears promising.
Bortezomib does not appear to have appreciable
anti-tumor activity in patients with DLBCL or HL.
Demonstration of durable complete and partial
responses to monotherapy with the mTOR inhibitors
(everolimus, temsirolimus, and ridaforolimus) in phase
I/II monotherapy trials support further study of this
class of compounds in phase III trials.
Treatment with bortezomib or the mTOR inhibitors is
relatively well-tolerated, especially in these cohorts
of heavily pretreated patients. The most common dose-
limiting toxicities associated with bortezomib (1.3 or 1.5
mg/m
2 twice weekly) were peripheral neuropathy, fati-
gue, and neutropenia. Similarly, the adverse events asso-
ciated with the mTOR inhibitors were generally
manageable; thrombocytopenia, neutropenia, and ane-
mia were the most commonly reported hematologic
toxicities. Starting doses of 10 mg/day for everolimus
(with reductions to 5 mg/day if needed) and temsiroli-
mus (175 mg/week for 3 weeks then 75 mg/week) are
supported by the clinical trial data. Hypercholesterole-
mia or hypertriglyceridemia have been reported with the
mTOR inhibitors [40,44,45], and one group of investiga-
tors recommends treating this adverse event with statins
in patients continuing on long-term temsirolimus treat-
ment [41].
Pulmonary toxicity associated with the mTOR inhibi-
tors is an issue that needs to be carefully monitored and
better understood. Dyspnea, cough, and pulmonary infil-
trates have been observed in patients treated with evero-
limus and temsirolimus [38,42,44,45]. However, these
symptoms may also be associated with infection or the
tumor itself, both of which should be ruled out before
attributing causality to the mTOR inhibitor. In our
study of everolimus in patients with HL, we did not
consider asymptomatic pulmonary infiltrates to be dose
limiting; rather we reduced the dose of everolimus only
when patients became symptomatic (eg, dyspnea on
exertion or cough) [45].
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the mTOR inhibitors everolimus and temsirolimus in
DLBCL and MCL, suggests that these agents may one
day have a place in the treatment armamentarium for
aggressive lymphomas. Results of monotherapy trials are
encouraging, and the use of bortezomib, everolimus, and
temsirolimus in combination with chemotherapy regi-
mens currently is being studied with the goal of maxi-
mizing the response and overall survival in patients with
aggressive lymphomas.
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